SIPCO LLC v. Jasco Products Company LLC

CourtDistrict Court, W.D. Oklahoma
DecidedMay 29, 2024
Docket5:19-cv-00709
StatusUnknown

This text of SIPCO LLC v. Jasco Products Company LLC (SIPCO LLC v. Jasco Products Company LLC) is published on Counsel Stack Legal Research, covering District Court, W.D. Oklahoma primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
SIPCO LLC v. Jasco Products Company LLC, (W.D. Okla. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF OKLAHOMA

SIPCO, LLC, ) ) Plaintiff, ) ) v. ) Case No. CIV-19-709-PRW ) JASCO PRODUCTS COMPANY, LLC, ) ) Defendant. )

ORDER Before the Court is Defendant’s Partial Motion to Dismiss Plaintiff’s Second Amended Complaint as to the ’304 and ’425 Patents (Dkt. 41). For the reasons that follow, the Motion (Dkt. 41) is GRANTED. Background In 2019, Plaintiff SIPCO, LLC brought this patent infringement lawsuit against Defendant Jasco Products Company, LLC. The now-operative Second Amended Complaint (Dkt. 38) alleges infringement of four patents owned by Plaintiff. At issue in the instant Partial Motion to Dismiss are claims related to only two of those patents: the ’304 and ’425 patents.1 Because the parties now agree that the claims related to the ’425 patent should be dismissed, the Court limits its discussion of the background of this dispute to the ’304 patent.

1 U.S. Patent No. 8,335,304; U.S. Patent No. 7,650,425. By all accounts, the ’304 patent has a somewhat unique and complicated history. The patent application eventually giving rise to the ’304 patent was initially filed with the

United States Patent and Trademark Office (“PTO”) in July of 2008. On October 20, 2010, the PTO issued an office action rejecting the application due to obviousness-type double patenting2—a doctrine that “prohibit[s] a party from obtaining an extension of the right to exclude through claims in a later patent that are not patentably distinct from claims in a commonly owned earlier patent.”3 The office action stated that certain claims in the ’304 patent application were “not patentably distinct” from claims in several pre-existing

patents, including the ’267 patent.4 The PTO, however, offered Plaintiff a way out of the obviousness-type double patenting issue. “A timely filed terminal disclaimer,” the office action explained, “may be used to overcome actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting . . . patent is shown to be commonly owned with this application.”5

2 See Office Action (Dkt. 46, Ex. 1), at 4–5. 3 Eli Lilly & Co. v. Barr Lab'ys, Inc., 251 F.3d 955, 967 (Fed. Cir. 2001). 4 Office Action (Dkt. 46, Ex. 1), at 4–5; U.S. Patent No. 6,430,267. 5 Office Action (Dkt. 46, Ex. 1), at 4. Terminal disclaimers can be used to overcome a double patenting rejection by “includ[ing] a provision that the patent or any patent issuing from the application is only enforceable for and during such period that it is owned by the same party (or parties) that owns the other patent[.]” Definition of Double Patenting, Manual of Patent Examining Procedure § 804. In effect, such a provision ties the expiration of the second patent to the first, ensuring that a patent holder does not receive an unjustified extension of the first patent term. See, e.g., Boehringer Ingelheim Intern. GmbH v. Barr Lab’ys, Inc., 592 F.3d 1340, 1346–47 (Fed. Cir. 2010). On March 21, 2011, Plaintiff filed its response to the office action. In it, Plaintiff explained that it would submit terminal disclaimers “to overcome the nonstatutory double

patenting rejection,” as the patents identified by the office action, including the ’267 patent, were “commonly owned by the present Applicant.”6 That same day, Plaintiff filed its terminal disclaimer to the ’267 patent.7 In the disclaimer Plaintiff “agree[d] that any patent so granted on the [’304 patent] application shall be enforceable only for and during such period that it and the [’267] patent are commonly owned.”8 A year and a half later, in reliance on the terminal disclaimers, the PTO issued the ’304 patent.9

As it turns out, Plaintiff’s statement in the March 2011 response—that it owned the ’267 patent—wasn’t true. At the time Plaintiff filed the response and terminal disclaimer, Plaintiff did not own the ’267 patent. Nor has it ever owned the ’267 patent. Both parties now believe that the PTO’s 2010 office action made a mistake. As Plaintiff explains, “[t]he ’267 patent, which is owned by Nokia Networks Oy, is not in the

same family as the ‘304 patent application or the other patents cited in the rejection; its subject matter is entirely unrelated to the subject matter of the ’304 patent application or of the other patents cited in the rejection.”10 Plaintiff does (and did) own the ’268 patent.11

6 Resp. to Office Action (Dkt. 46, Ex. 2), at 13. 7 See ’267 Terminal Disclaimer (Dkt. 41, Ex. 3). 8 ’267 Terminal Disclaimer (Dkt. 41, Ex. 3) (emphasis added). 9 See ’304 Patent (Dkt. 38, Ex. 5). 10 Pl.’s Suppl. Br. (Dkt. 53), at 2. 11 U.S. Patent No. 6,430,268. Unlike the ’267 patent, the ’268 patent is “in the same family as the ’304 patent application and the other patents cited in the rejection and does relate to the subject matter of the ’304 patent application.”12 The reference to the ’267 patent in the 2010 office action was likely

nothing more than a “transcribing error.”13 An error that Plaintiff compounded when, in response to the office action, it represented to the PTO that it indeed owned the ’267 patent. Plaintiff first attempted to correct the error in November 2016 with a petition requesting withdrawal of the ’267 terminal disclaimer and replacement with a new ’268 terminal disclaimer.14 The PTO dismissed the petition in October 2017, finding that,

pursuant to an update to the Manual of Patent Examining Procedure (“MPEP”), “withdrawal of the terminal disclaimer would not be warranted even if the error in the terminal disclaimer consisted of a transposition error.”15 Under the new guidance, the PTO would not withdraw terminal disclaimers in issued patents with inadvertent errors, but would allow patentees to file an explanation of the error along with additional terminal

disclaimers disclaiming the correct patents.16 The PTO gave Plaintiff two months to request reconsideration of the dismissal decision. Rather than request reconsideration, Plaintiff filed a new, stand-alone ’268

12 Pl.’s Suppl. Br. (Dkt. 53), at 2. 13 Pl.’s Suppl. Br. (Dkt. 53), at 2. 14 Pet. (Dkt. 41, Ex. 5). 15 Decision on Pet. (Dkt. 41, Ex. 6). 16 Decision on Pet. (Dkt. 41, Ex. 6). terminal disclaimer in February 2018.17 By that time, the ’304 patent had already expired pursuant to another terminal disclaimer.18

Defendant now moves to dismiss Plaintiff’s claims relating to the ’304 patent on the grounds that the ’267 terminal disclaimer and the lack of shared ownership rendered the ’304 patent unenforceable throughout its life. Legal Standard In reviewing a Fed. R. Civ. P. 12(b)(6) motion to dismiss, the Court must satisfy itself that the pleaded facts state a claim that is plausible.19 All well-pleaded allegations in

the complaint must be accepted as true and viewed “in the light most favorable to the plaintiff.”20 “The court’s function on a Rule 12(b)(6) motion is not to weigh potential evidence that the parties might present at trial, but to assess whether the plaintiff’s complaint alone is legally sufficient to state a claim for which relief may be granted.”21 At this stage, a plaintiff bears the “obligation to provide the grounds of [their] entitle[ment] to

relief,” which requires “more than labels and conclusions, and a formulaic recitation of the elements of a cause of action will not do.”22 The pleaded facts must be sufficient to

17 ’268 Terminal Disclaimer (Dkt. 41, Ex. 7). 18 ’764 Terminal Disclaimer (Dkt. 41, Ex. 1). 19 Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007). 20 Alvarado v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Mahn v. Harwood
112 U.S. 354 (Supreme Court, 1884)
Neitzke v. Williams
490 U.S. 319 (Supreme Court, 1989)
Warner-Jenkinson Co. v. Hilton Davis Chemical Co.
520 U.S. 17 (Supreme Court, 1997)
Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.
535 U.S. 722 (Supreme Court, 2002)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Dubbs Ex Rel. Dubbs v. Head Start, Inc.
336 F.3d 1194 (Tenth Circuit, 2003)
Alvarado v. KOB-TV, L.L.C.
493 F.3d 1210 (Tenth Circuit, 2007)
In Re Fallaux
564 F.3d 1313 (Federal Circuit, 2009)
Application of Max O. Robeson
331 F.2d 610 (Customs and Patent Appeals, 1964)
In Re Yamazaki
702 F.3d 1327 (Federal Circuit, 2012)
In Re Hubbell
709 F.3d 1140 (Federal Circuit, 2013)
stc.unm v. Intel Corporation
754 F.3d 940 (Federal Circuit, 2014)
Inre: Dinsmore
757 F.3d 1343 (Federal Circuit, 2014)
Japanese Foundation for Cancer Research v. Lee
773 F.3d 1300 (Federal Circuit, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
SIPCO LLC v. Jasco Products Company LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sipco-llc-v-jasco-products-company-llc-okwd-2024.